SCHEMBL5145161

SCHEMBL5145161

COc1cc2ccc(Oc3cc4sc(N)nc4cc3F)nc2cc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
ILK Q13418 12/20 0.42
PIK3CD O00329 1/20 0.41
PIP5K1C O60331 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
AXL P30530 1/20 0.39
GFER P55789 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741739 0.81 ILK (0.56) CYP3A4CYP1A2CYP2C19ILKAXL
SCHEMBL2678487 0.81 ILK (0.56) CYP3A4CYP1A2CYP2C19ILKAXL
SCHEMBL2552313 0.78 CYP3A4 (0.53) CYP3A4CYP1A2CYP2C19ILKPIK3CD
SCHEMBL31114638 0.78 CYP3A4 (0.59) CYP3A4CYP1A2CYP2C19PIK3CDPIP5K1C
SCHEMBL9722790 0.78 CYP3A4 (0.59) CYP3A4CYP1A2CYP2C19PIK3CDPIP5K1C
SCHEMBL371554 0.77 FGFR2 (0.48) AXL
SCHEMBL20525612 0.72 ILK (0.38) CYP3A4CYP1A2CYP2C19ILKALDH1A1
SCHEMBL21186003 0.71 TP53 (0.59) CYP3A4CYP1A2CYP2C19PIK3CAPI4KA
SCHEMBL8435128 0.71 CYP3A4 (0.55) CYP3A4CYP1A2CYP2C19ILKPIK3CD
SCHEMBL21186004 0.71 AXL (0.49) CYP3A4CYP1A2CYP2C19ILKPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET CYP3A4 1264/4885CYP1A2 3232/4885CYP2C19 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.